Literature DB >> 12512033

Model for end-stage liver disease (MELD) and allocation of donor livers.

Russell Wiesner1, Erick Edwards, Richard Freeman, Ann Harper, Ray Kim, Patrick Kamath, Walter Kremers, John Lake, Todd Howard, Robert M Merion, Robert A Wolfe, Ruud Krom.   

Abstract

BACKGROUND & AIMS: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. Our aim was to assess the capability of the Model for End-Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list.
METHODS: The MELD model predicts liver disease severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful in predicting mortality in patients with compensated and decompensated cirrhosis. In this study, we prospectively applied the MELD score to estimate 3-month mortality to 3437 adult liver transplant candidates with chronic liver disease who were added to the OPTN waiting list at 2A or 2B status between November, 1999, and December, 2001.
RESULTS: In this study cohort with chronic liver disease, 412 (12%) died during the 3-month follow-up period. Waiting list mortality increased directly in proportion to the listing MELD score. Patients having a MELD score <9 experienced a 1.9% mortality, whereas patients having a MELD score > or =40 had a mortality rate of 71.3%. Using the c-statistic with 3-month mortality as the end point, the area under the receiver operating characteristic (ROC) curve for the MELD score was 0.83 compared with 0.76 for the Child-Turcotte-Pugh (CTP) score (P < 0.001).
CONCLUSIONS: These data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.

Entities:  

Mesh:

Year:  2003        PMID: 12512033     DOI: 10.1053/gast.2003.50016

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  538 in total

1.  A C-index for recurrent event data: Application to hospitalizations among dialysis patients.

Authors:  Sehee Kim; Douglas E Schaubel; Keith P McCullough
Journal:  Biometrics       Date:  2017-08-03       Impact factor: 2.571

2.  Value of the SOFA score as a predictive model for short-term survival in high-risk liver transplant recipients with a pre-transplant labMELD score ≥ 30.

Authors:  Harald Schrem; Melanie Reichert; Benedikt Reichert; Thomas Becker; Frank Lehner; Moritz Kleine; Hüseyin Bektas; Kai Johanning; Christian P Strassburg; Jürgen Klempnauer
Journal:  Langenbecks Arch Surg       Date:  2011-12-06       Impact factor: 3.445

3.  Current Management of Alcohol-Associated Liver Disease.

Authors:  Faisal A Siddiqi; Krishna C Sajja; Nyan L Latt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-11

Review 4.  Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

Authors:  J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó
Journal:  Aliment Pharmacol Ther       Date:  2011-09-20       Impact factor: 8.171

5.  S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.

Authors:  Valentina Medici; Maria C Virata; Janet M Peerson; Sally P Stabler; Samuel W French; Jesse F Gregory; Anthony Albanese; Christopher L Bowlus; Sridevi Devaraj; Edward A Panacek; John R Richards; Charles H Halsted
Journal:  Alcohol Clin Exp Res       Date:  2011-11       Impact factor: 3.455

6.  Intraoperative portal vein blood flow predicts allograft and patient survival following liver transplantation.

Authors:  Austin L Spitzer; Andre A S Dick; Ramasamy Bakthavatsalam; Jeffrey B Halldorson; Paolo R Salvalaggio; Jorge D Reyes; James D Perkins
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

7.  Model for end-stage liver disease exceptions committee activity in Argentina: does it provide justice and equity among adult patients waiting for a liver transplant?

Authors:  Lucas McCormack; Adrián Gadano; Javrer Lendoire; Emilio Quiñonez; Oscar Imventarza; Oscar Andriani; Lorenzo Toselli; Octavio Gil; Gabriel Gondolesi; Liliana Bisigniano; Eduardo De Santibañes
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

Review 8.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

9.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

10.  Using the Minimally Invasive Impella 5.0 via the Right Subclavian Artery Cutdown for Acute on Chronic Decompensated Heart Failure as a Bridge to Decision.

Authors:  Aditya Bansal; Jay K Bhama; Rajan Patel; Sapna Desai; Stacy A Mandras; Hamang Patel; Tyrone Collins; John P Reilly; Hector O Ventura; P Eugene Parrino
Journal:  Ochsner J       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.